We are very excited to announce the appointment of Frank Zenke as Chief Scientific Officer at FoRx Therapeutics! With more than 20 years of pharma industry experience, Frank is a highly respected leader in oncology drug discovery and development with a particular focus on DNA Damage Response (DDR) pathways. Welcome to the team, Frank, and we are very much looking forward to working with you! https://lnkd.in/gkxfsWY management-team
Great addition to you team. Congrats Tarig Bashir!
Proud that FoRx Therapeutics was featured in a recent Labiotech article: https://lnkd.in/d_YZ2_xz
We are thrilled to announce today the nomination of our first preclinical development candidate, FORX-428, an inhibitor of Poly(ADP-ribose) glycohydrolase (PARG). FORX-428 has strong best-in-class potential and is being developed for the treatment of solid tumors. IND-enabling activities have already been initiated. FORX-428 is an oral, highly potent and selective inhibitor of PARG that shows excellent single-agent activity in multiple relevant preclinical tumor models. The compound is well tolerated and demonstrates a favorable pharmacological and safety profile. FORX-428 has the potential to achieve transformative outcomes in patients with cancers of high medical need or affected by therapy resistance. Please read the full press release here: https://lnkd.in/eUX35dD4
🔬 Exciting News from FoRx Therapeutics! 🎉Join us at AACR2024 in San Diego as we present our latest findings on our PARG inhibitor program. Meet our team, including Olivier Querolle, Frank Zenke, and Tarig Bashir, and discover how our research is shaping the future of cancer therapy. See you there! #AACR2024 #CancerResearch #FoRxTherapeutics
🌟 Exciting News Alert! 🌟 FoRx Therapeutics is thrilled to welcome esteemed professionals Timothy Yap from the MD Anderson Cancer Center, Houston, USA, and Christopher Lord from The Institute of Cancer Research, London, UK, to our Scientific Advisory Board! Timothy Yap, a renowned Medical Oncologist and Physician-Scientist, specializes in the clinical assessment and development of innovative therapeutics targeting DNA Damage Response (DDR) pathways in cancer. Christopher Lord, an expert in cancer genomics, pioneers genetic concepts such as synthetic lethality for cancer treatment. Their world class expertise will further elevate our mission in advancing groundbreaking therapies targeting the DDR. Together with our current SAB members Thanos Halazonetis from the University Geneva, Patrick Verhoest from Pfizer, and Dirk Laurent from Merck KGaA, we're forging new frontiers in the fight against cancer!
Sr Director Discovery Pharmacology at Merck Healthcare
1yAll the best!